Health & Evidence Library
Evidence guides to reproductive, hormonal, sexual, urinary, pregnancy-related, and sex-specific health questions.
44 guides · Page 1 of 1
Stress incontinence leaks with a cough; urge incontinence follows sudden urgency. Pelvic floor and bladder training are first-line for both.
How to tell ordinary PMS from PMDD: the severity, timing, and functional impairment that mark a treatable disorder, plus what the evidence supports.
Plain facts about genital herpes: how HSV spreads, what type-specific testing can and cannot tell you, and what antiviral treatment achieves.
Learn when AUA and ASRM guidance considers varicocele repair, what semen changes studies report, and why pregnancy and live birth matter beyond a lab result.
Women's enrollment has improved, but evidence gaps persist in preclinical design, pregnancy, menopause, condition-specific funding, and subgroup analysis.
What WHI follow-up, ELITE, and current guidance do and do not show about when menopausal hormone therapy is started.
TRAVERSE found cardiovascular noninferiority for testosterone gel in selected men with confirmed hypogonadism and cardiovascular risk.
Why endometriosis symptoms are missed, what normal imaging can and cannot rule out, and how 2026 guidance supports earlier clinical diagnosis.
FDA removed cardiovascular boxed-warning language and added blood-pressure warnings in 2025, then requested more label changes in June 2026.
The FDA lowered zolpidem starting doses for women after finding slower clearance and morning impairment risk. Learn what the case does and does not prove.
How ERSPC and PLCO differed in control-group screening, follow-up, and design, and why PSA screening remains a preference-sensitive decision.
What ProtecT found at 15 years about prostate cancer death, metastasis, progression, treatment crossover, and quality-of-life tradeoffs.
How collection, variation, semen volume, sperm count, motility, morphology, vitality, and WHO sixth-edition limits fit fertility evaluation.
The USPSTF gives hormone therapy a Grade D for preventing chronic disease. Here is why that verdict is separate from treating menopause symptoms.
A neutral explainer of the FDA's November 2025 removal of the menopausal hormone therapy boxed warning, and what the label change does not mean.
How the PRECISION randomized trial tested putting an MRI ahead of prostate biopsy, and what its findings do and do not settle.
How to interpret a dense-breast notification and what the DENSE randomized trial found about adding a screening MRI, benefit and harm side by side.
The 2023 PCOS guideline treats the syndrome as cardiometabolic, yet recommends the OGTT, HbA1c and lipids over routine fasting-insulin testing.
Why bisphosphonates prevent far more hip fractures than they cause rare atypical femur fractures, and why a drug holiday is a reassessment rather than a rule.
What the SKYLIGHT trials and FDA approval of fezolinetant reveal about a modest hot flash benefit set against a boxed liver warning.
How the SWAN cohort reframes midlife metabolic change in women as a time-locked event tied to the final menstrual period, not ordinary aging.
How the ASPRE trial and the USPSTF grade B aspirin recommendation for preeclampsia differ on dose, screening, and absolute risk.
How the FDA clearance and the 2025 ACS guideline weigh the accuracy of a self-collected HPV sample against a clinician-collected one.
How the Prostate Cancer Prevention Trial's alarming Gleason 7 signal turned out to be mostly a measurement artifact, with survival even over two decades.
What a defensible low testosterone diagnosis requires, and how to read a Low-T marketing claim against the published evidence.
A headline can say a contraceptive "triples" clot risk while the true change is a handful of extra cases per 10,000 users. Here is how to read both numbers.
What trials of alpha-blockers, 5-alpha-reductase inhibitors, and combination therapy actually show about easing urinary symptoms versus slowing the disease.
What the GOTEBORG-2 screening trial found when a 4Kscore blood test was placed between an elevated PSA and the MRI and biopsy that usually follow.
The short list of preventive screenings for men with strong guideline backing, sorted by the age, habit, or risk score that should prompt each one.
How urinary tract infection prevention and treatment actually work: when a UTI needs antibiotics, when it does not, how to avoid repeats, and the red flags.
A well-woman visit is a yearly preventive checkup for women. See what it includes and how the priorities shift by age, from screening to contraception.
Should you get a PSA prostate cancer screening? For men 55 to 69 it is a shared decision. Here are the modest benefits, the real harms, and how to weigh them.
Preconception health, explained simply: start folic acid early, steady any chronic conditions, review medications and vaccines, and prepare at your own pace.
Osteoporosis screening for women, explained: who needs a bone density test, at what age, and what genuinely protects bone through and after menopause.
An evidence-based guide to menopause and perimenopause symptoms and treatment: how long hot flashes last, when hormone therapy fits, and nonhormonal options.
Men's mental health is a recognition and access problem, not a character flaw. Why men avoid care, the signs of depression to watch for, and where to start.
A plain guide to men's health checkups: the evidence-based screenings and shared decisions primary care actually covers, matched to age and risk.
Low testosterone is diagnosed by symptoms plus repeated low morning tests, not marketing. Here is what testosterone therapy for men can and cannot do.
Iron deficiency and heavy periods often go together. Learn how to tell if a period is heavy, when to check ferritin, and how treatment works.
Heart health for men comes down to five numbers: blood pressure, LDL, blood sugar, weight, and tobacco. See the targets and habits to raise with your clinician.
Erectile dysfunction as a health signal can point to vascular, metabolic, or hormonal problems, sometimes years early. Here is why it is worth raising.
Contraception in primary care, explained simply: the five method groups, how effectiveness works (typical vs perfect use), and how to choose a fit.
Colorectal cancer screening now starts at 45 for average-risk adults. Compare colonoscopy vs FIT and stool DNA tests, and pick the one you will finish.
How current cervical cancer screening works, including preferred primary high-risk HPV testing, Pap and co-testing intervals, and qualified self-collection.